Oppenheimer Holdings, Inc. reaffirmed their hold rating on shares of CytomX Therapeutics, Inc. (NASDAQ:CTMX) in a research note released on Wednesday morning.

A number of other analysts have also recently weighed in on the stock. Bank of America Corporation raised their target price on shares of CytomX Therapeutics from $30.00 to $34.00 and gave the stock a buy rating in a report on Wednesday. Nomura raised their target price on shares of CytomX Therapeutics to $44.00 and gave the stock a buy rating in a report on Wednesday. Wedbush set a $37.00 target price on shares of CytomX Therapeutics and gave the stock a buy rating in a report on Wednesday. ValuEngine lowered shares of CytomX Therapeutics from a hold rating to a sell rating in a research note on Friday, September 15th. Finally, Jefferies Group LLC set a $25.00 price objective on shares of CytomX Therapeutics and gave the stock a buy rating in a research note on Friday, August 25th. Two investment analysts have rated the stock with a sell rating, three have issued a hold rating and six have assigned a buy rating to the company. CytomX Therapeutics has an average rating of Hold and an average target price of $32.67.

Shares of CytomX Therapeutics (NASDAQ CTMX) traded down 2.54% on Wednesday, hitting $21.50. The company had a trading volume of 444,671 shares. The company has a 50-day moving average of $17.37 and a 200 day moving average of $15.69. The stock’s market cap is $792.64 million. CytomX Therapeutics has a 12 month low of $9.85 and a 12 month high of $24.67.

CytomX Therapeutics (NASDAQ:CTMX) last issued its earnings results on Monday, August 7th. The biotechnology company reported ($0.69) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.39) by ($0.30). The business had revenue of $8.75 million for the quarter, compared to the consensus estimate of $4.95 million. CytomX Therapeutics had a negative return on equity of 84.61% and a negative net margin of 206.33%. Analysts anticipate that CytomX Therapeutics will post ($1.47) EPS for the current fiscal year.

COPYRIGHT VIOLATION NOTICE: “CytomX Therapeutics’ (CTMX) “Hold” Rating Reiterated at Oppenheimer Holdings, Inc.” was first posted by Watch List News and is the property of of Watch List News. If you are accessing this piece of content on another site, it was stolen and republished in violation of international copyright and trademark law. The legal version of this piece of content can be accessed at https://www.watchlistnews.com/cytomx-therapeutics-ctmx-hold-rating-reiterated-at-oppenheimer-holdings-inc/1615715.html.

In related news, major shareholder Robert I. Tepper sold 24,777 shares of the firm’s stock in a transaction that occurred on Wednesday, October 4th. The shares were sold at an average price of $24.34, for a total value of $603,072.18. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, major shareholder Robert I. Tepper sold 20,000 shares of the firm’s stock in a transaction that occurred on Tuesday, September 19th. The stock was sold at an average price of $18.00, for a total transaction of $360,000.00. Following the completion of the transaction, the insider now directly owns 54,293 shares of the company’s stock, valued at approximately $977,274. The disclosure for this sale can be found here. Insiders sold a total of 177,794 shares of company stock valued at $3,806,089 in the last ninety days. Company insiders own 4.70% of the company’s stock.

A number of institutional investors have recently bought and sold shares of CTMX. Legal & General Group Plc boosted its stake in CytomX Therapeutics by 28.6% in the 2nd quarter. Legal & General Group Plc now owns 6,448 shares of the biotechnology company’s stock worth $101,000 after purchasing an additional 1,434 shares during the period. First Quadrant L P CA acquired a new position in CytomX Therapeutics in the 2nd quarter worth approximately $160,000. Cubist Systematic Strategies LLC acquired a new position in CytomX Therapeutics in the 2nd quarter worth approximately $174,000. Goldman Sachs Group Inc. acquired a new position in CytomX Therapeutics in the 1st quarter worth approximately $190,000. Finally, Voya Investment Management LLC acquired a new position in CytomX Therapeutics in the 2nd quarter worth approximately $203,000. 59.97% of the stock is owned by hedge funds and other institutional investors.

About CytomX Therapeutics

CytomX Therapeutics, Inc is a clinical-stage, oncology-focused biopharmaceutical company. The Company uses its Probody technology platform to create cancer immunotherapies against clinically validated targets, as well as to develop cancer therapeutics against difficult-to-drug targets. Its pipeline is focused on the development of therapies in a set of modalities: Probody cancer immunotherapies, Probody drug conjugates, T-cell engaging Probody bispecifics and ProCAR-NK cell therapies.

Analyst Recommendations for CytomX Therapeutics (NASDAQ:CTMX)

Receive News & Ratings for CytomX Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CytomX Therapeutics Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.